Breaks Categories: News

WednesdayAug 02, 2023 1:04 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site

IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as pharmaceutical active agents for the treatment of Alzheimer’s and, in pre-clinical and phase 1 studies, has shown the potential to be effective in ameliorating Aβ plaques and…

Continue Reading

FridayJul 28, 2023 12:52 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has incorporated a new wholly owned subsidiary: Lexaria Nutraceutical Corp., or LEXX Nutra. According to the announcement, LEXX Nutra was established to support Lexaria’s overall strategy of maximizing the potential for its patented DehydraTECH(TM) technology in a variety of markets. The company issued an exclusive perpetual license to LEXX Nutra, giving the new subsidiary rights to utilize, or sublicense the use of, DehydraTECH in an array of ways, including creating consumer packaged goods (“CPG”) and/or intermediate ingredients composed of any molecule except those associated with nicotine or cannabis. LEXX Nutra…

Continue Reading

FridayJul 21, 2023 11:31 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare…

Continue Reading

ThursdayJul 20, 2023 12:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market. Among the highlights, the company reported a 123% quarter-over-quarter increase in revenues. “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth,” said Eric A. Adams, InMed’s president and CEO. “As demand for minor cannabinoids continues to increase, we…

Continue Reading

WednesdayJul 19, 2023 12:03 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it was granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (“USPTO”). According to the update, U.S. patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. The company’s superior DehydraTECH processing and sublingual compositions have now been recognized through exceptional scientific study results as well as…

Continue Reading

TuesdayJul 18, 2023 1:21 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to have six posters accepted for presentation at AAIC 2023, a prestigious meeting of leading Alzheimer’s disease experts and pharmaceutical innovators,” said Ram Mukunda, CEO of IGC. “The data being presented at AAIC from our phase 1 clinical trial of IGC-AD1 demonstrates the positive impact of…

Continue Reading

MondayJul 17, 2023 1:14 pm

CannabisNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our…

Continue Reading

FridayJul 14, 2023 1:21 pm

CannabisNewsBreaks – Cannabis Drinks Expo Gear Up for 2023 Events with ‘Growing the Category’ Theme and Focus

Cannabis Drinks Expo (“CDE”) is preparing for its 2023 events, which include shows at San Francisco and Chicago; the San Francisco expo is slated for July 27, 2023, and the Chicago event is scheduled for Aug. 1, 2023. Last year’s events brought together key players in the industry, including MSO’s, dispensaries, cannabis growers, packaging companies, copackers, flavor suppliers, cannabis drinks brands and service providers, and this year’s events are anticipated to accomplish the same thing — and then some. Expected to be two of the largest global gatherings of cannabis drinks professionals around the world, this year’s events will continue…

Continue Reading

ThursdayJul 13, 2023 3:24 pm

CannabisNewsBreaks — Lift Events and Experiences Announces Inaugural US Cannabis Food & Beverage Event

Lift Events and Experiences will be hosting its first U.S. event: Lift San Francisco. The two-day event will be held on Aug. 3–4, 2023, at the Moscone Convention Center in San Francisco. According to the announcement, the event will feature the inaugural Taste at Lift: Cannabis Food & Beverage Experience, which is designed to allow attendees to participate in exclusive demos, in-depth presentations and expert panels led by the top innovators in the cannabis food, beverage and hospitality space. The first day of the Lift San Francisco event will feature the Lift Cannabis Business Conference & Arcview Investment Summit, with Taste…

Continue Reading

WednesdayJul 12, 2023 11:34 am

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results as it progresses through phase 2B trials. We are delighted with the positive headway we are making in clinical trials, and we remain confident in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer’s and to manage devastating symptoms…

Continue Reading